PD-L1 Targeting Molecular Imaging of Solid Tumors
Not Applicable
Recruiting
- Conditions
- Gastrointestinal Tumors
- Interventions
- Other: 68Ga-WL12 PET/CT
- Registration Number
- NCT04629326
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Brief Summary
The objective of the study is to constrcut a noninvasive approach WL12 PET/CT to detect the PD-L1 expression of tumor lesions in patients with gastrointestinal tumors and to identify patients benefiting from anti-PD-1/L1 treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
-
- Aged >18 years old; ECOG 0 or 1;
-
- Patients with Gastrointestinal tumors;
-
- Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1);
-
- life expectancy >=12 weeks.
Exclusion Criteria
-
- Significant hepatic or renal dysfunction;
-
- Is pregnant or ready to pregnant;
-
- Cannot keep their states for half an hour;
-
- Refusal to join the clinical study;
-
- Suffering from claustrophobia or other mental diseases;
-
- Any other situation that researchers think it is not suitable to participate in the experiment.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Imaging cohort 68Ga-WL12 PET/CT All study participants will be allocated to this arm (single-arm study).Study participants will undergo 68Ga-WL12 PET/CT scans
- Primary Outcome Measures
Name Time Method Standardized uptake value（SUV） 2 years The uptake of the tracer in the primary and metastatic tumor lesions by measuring standardized uptake value（SUV）on PET/CT
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Beijing Cancer Hospital
🇨🇳Beijing, Beijing, China